Core Viewpoint - Century Huatong has been found guilty of multiple violations related to financial reporting, leading to ongoing compensation claims from investors [2][3]. Group 1: Legal Violations - From 2018 to 2022, Century Huatong's annual reports contained false records regarding goodwill, including a failure to conduct goodwill impairment tests in 2018, resulting in an under-provision of goodwill impairment by 62.363 million yuan [2][3]. - The company incorrectly disclosed the original value of goodwill in its annual reports from 2019 to 2022, and failed to report segments in accordance with accounting standards [3][4]. - Between 2020 and 2022, Century Huatong did not perform required goodwill impairment tests, leading to inflated and deflated profits in its financial statements [4]. Group 2: Revenue Misrepresentation - Century Huatong was found to have fabricated software copyright transfer transactions, which resulted in inflated revenue for 2020 [4]. - The company prematurely recognized revenue from the software copyright transfer of "Rainbow Alliance," inflating 2020 revenue and profits while deflating those of 2021 [4]. - The report regarding the completion of performance commitments for the year 2020 contained false records [4]. Group 3: Investor Compensation - Investors who purchased Century Huatong stock between April 27, 2019, and July 25, 2023, and sold or continued to hold the stock after July 25, 2023, are eligible to initiate compensation claims [2][4].

Core Viewpoint - The article discusses the ongoing legal actions against Huichen Co., Ltd. (慧辰股份) regarding investor claims due to alleged financial misconduct, including inflated revenue and profits through fictitious business activities and contracts [2][3][4]. Group 1: Legal Proceedings - On January 20, 2026, Shanghai Jiucheng Law Firm, represented by lawyer Xu Feng, submitted another case for investor claims against Huichen Co., Ltd. to the Shanghai Financial Court [1]. - Xu Feng highlighted that there have been precedents of investor victories in similar claims, and the legal team is actively pursuing further cases while accepting new claims from other investors [1][4]. Group 2: Regulatory Findings - On December 22, 2023, Huichen Co., Ltd. announced that it received an administrative penalty decision from the Beijing Regulatory Bureau of the China Securities Regulatory Commission, confirming violations related to its acquisition of Xintang Puhua [3]. - The company acquired 48% of Xintang Puhua's shares in June 2017 and later increased its stake to 70% by December 2020, making it a controlling subsidiary [3]. Group 3: Financial Misconduct - Xintang Puhua allegedly inflated its revenue and profits by fabricating business transactions, signing contracts without commercial substance, and prematurely recognizing project income, leading to false disclosures in Huichen's IPO prospectus and subsequent annual reports from 2020 to 2022 [2][3]. Group 4: Investor Claims Timeline - Xu Feng indicated that investors who purchased Huichen shares before February 10, 2023, and sold or held them after that date are eligible to file claims, with the deadline approaching rapidly [4].

Group 1 - The core issue involves a lawsuit against Huichen Co., Ltd. (688500) for stock compensation, with a precedent of investor victories in similar cases [1] - The company received an administrative penalty from the Beijing Regulatory Bureau of the CSRC on December 22, 2023, due to violations related to inflated revenue and profits through fictitious business activities and contracts [1] - Huichen Co., Ltd. acquired a 48% stake in Xintang Puhua in June 2017, and later increased its stake to 70% by December 2020, leading to the latter becoming a subsidiary [1] Group 2 - Investors who purchased Huichen Co., Ltd. stock before February 10, 2023, and sold or held it after that date are eligible to file for compensation, with a deadline approaching [2] - The law firm representing the investors has a history of successful claims, having represented nearly 200 stocks with victories or settlements, and is currently handling around 300 ongoing cases [2] - There are no fees for investors who do not receive compensation, emphasizing the risk-free nature of the legal process for claimants [2]

Group 1 - The law firm Shanghai Jiucheng is representing investors in lawsuits against Xilong Science and Puli Pharmaceutical for false statements leading to financial losses [1][2] - Xilong Science was found to have inflated its revenue by approximately 597.65 million yuan in 2020, 1.46 billion yuan in 2021, and 785.35 million yuan in the first half of 2022, affecting its reported profits significantly [1] - Puli Pharmaceutical reported inflated revenues of about 514.60 million yuan in 2021 and 515.90 million yuan in 2022, with corresponding profit overstatements of 308.02 million yuan and 387.42 million yuan, respectively [2] Group 2 - Investors who purchased Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, or Xilong Science shares between April 29, 2021, and April 29, 2023, may still initiate claims for compensation [3] - The law firm has a history of successfully representing investors in similar cases, having handled nearly 200 cases resulting in victories or settlements [3]

Group 1 - The core point of the article highlights that Rongbai Technology has a financing balance of 1.81 billion, accounting for 7.64% of its market capitalization as of January 19 [2] - On January 18, Rongbai Technology announced that it received a notice of investigation from the China Securities Regulatory Commission, indicating potential issues with timely and accurate information disclosure [2] - Investors who suffered losses due to the company's information disclosure issues can participate in a compensation claim process, provided they purchased shares between the IPO and January 18, 2026, and held them until the market close on that date [2] Group 2 - The eighth meeting of the third supervisory board of Rongbai Technology was held on December 11, 2025, with all three supervisors present, complying with relevant regulations [3] - The board unanimously agreed to waive the notification period for the meeting and approved a proposal to cancel the supervisory board, change the registered capital, and amend the company’s articles of association [3] - Rongbai Technology is located in Ningbo, Zhejiang Province, primarily engaged in the manufacturing of computers, communications, and other electronic equipment [3]

Group 1 - Company Rongbai Technology received a financing buy-in of 365 million yuan and a financing repayment of 265 million yuan on January 19, resulting in a net financing buy-in of approximately 99.22 million yuan on that day [2] - On January 18, 2026, Rongbai Technology announced that it received a notice of investigation from the China Securities Regulatory Commission (CSRC) due to alleged misleading statements in a major contract announcement [2] - The CSRC decided to initiate an investigation against the company based on the Securities Law of the People's Republic of China and the Administrative Penalty Law of the People's Republic of China [2] Group 2 - On December 30, 2025, Rongbai Technology held its second extraordinary general meeting of shareholders, where all 9 directors and 3 supervisors were present [3] - The meeting approved several resolutions, including the cancellation of the supervisory board and changes to registered capital [3] - Legal representatives confirmed that the procedures for convening and holding the shareholders' meeting complied with relevant laws, regulations, and the company's articles of association [3]

Group 1 - The company Sunflower (300111) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation due to suspected violations of information disclosure laws [2] - Investors who purchased the stock between September 22, 2025, and December 25, 2025, and held it after the market closed on December 25, 2025, are eligible to apply for compensation for their losses [2] Group 2 - The company announced the termination of its plan to acquire 100% equity of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% equity of Zhejiang Beid Pharmaceutical Co., Ltd. through a share issuance and cash payment [4] - The CSRC's inquiry highlighted that Xipu Materials, based in Fujian Zhangzhou, has no actual production capacity at its factories in Zhangzhou and Lanzhou, despite being a core supplier for several wafer fabs [4] - The inquiry also requested detailed information on Xipu Materials' production capacity, including the status of approvals, construction, and production at its factories [4] Group 3 - Xipu Materials is primarily engaged in the research, manufacturing, and sales of high-end semiconductor materials, with core products including high-purity electronic gases and silicon-based precursors [5] - The inquiry requested financial details regarding Xipu Materials' revenue, costs, and gross margins for 2023 and 2024, as well as information on its transactions with Shanghai Deen Hong New Materials Technology Co., Ltd. [5] - Concerns were raised about potential adverse impacts on competition and independence due to the restructuring, as well as the legal issues faced by Xipu Materials' actual controller, which could affect asset transfers [5]

Core Viewpoint - Century Huatong is facing legal claims from investors due to false statements in its financial reports, particularly regarding goodwill impairment and revenue recognition issues [2][5][6] Group 1: Legal Proceedings and Investor Claims - Shanghai Jiucheng Law Firm is actively pursuing claims for investors affected by Century Huatong's false statements, with some cases already resulting in compensation [1][4] - Investors who purchased Century Huatong shares between April 27, 2019, and July 25, 2023, are eligible to file claims, even if they sold their shares for a profit after the disclosure date [1][6] Group 2: Regulatory Findings - On November 6, 2024, Century Huatong received an administrative penalty from the China Securities Regulatory Commission (CSRC) for false records in its annual reports from 2018 to 2022 [2][5] - The company failed to conduct goodwill impairment tests as required, resulting in an underreporting of goodwill impairment provisions by 62.363 million yuan in 2018 [5] - There were errors in the disclosure of goodwill values and segment reporting in annual reports from 2019 to 2022, which did not comply with accounting standards [6] Group 3: Revenue Recognition Issues - Century Huatong is accused of fabricating software copyright transfer transactions and prematurely recognizing revenue, leading to inflated revenues in 2020 and 2021 [6] - The company falsely reported the completion of performance commitments related to its software transactions, further misleading investors [6]

Core Viewpoint - The article discusses the ongoing legal actions against Derun Electronics (002055) due to allegations of financial misconduct, including false reporting and misrepresentation of financial data, leading to potential claims for investor compensation. Group 1: Allegations of Financial Misconduct - Derun Electronics is accused of fabricating revenue figures of CNY 394,584,426.91 and CNY 112,960,100 for the years 2020 and 2021 respectively, resulting in understated credit impairment losses of CNY 371,151,433.40 and CNY 66,393,093.51 [3] - In June 2022, the company allegedly misrepresented revenue by CNY 26,836,923.99 and understated credit impairment losses by CNY 5,060,996.46 through indirect financial support to its affiliates [2][3] Group 2: Impact on Financial Reports - The actions of Derun Electronics led to false disclosures in its annual reports for 2020 and 2021, as well as the semi-annual report for 2022, which contained misleading financial information [4] - The company’s non-public offering report issued on January 11, 2022, also referenced these inaccurate financial statements, further compounding the issue of misrepresentation [4] Group 3: Legal Recourse for Investors - Investors who purchased Derun Electronics stock between August 27, 2020, and December 30, 2023, and sold or continued to hold the stock after December 30, 2023, may still file for compensation [5]

Core Viewpoint - The article discusses the ongoing legal actions regarding investor claims against Yitong Century (宜通世纪), highlighting the company's financial misconduct and the potential for investors to seek compensation through legal channels [1][2][3]. Group 1: Legal Proceedings - On January 13, 2026, the Shanghai Jiucheng Law Firm, represented by lawyer Xu Feng, submitted another case for investor claims against Yitong Century to the Guangzhou Intermediate People's Court [1]. - Some previous investor claims handled by Xu Feng have already reached settlements, and the firm continues to accept new claims from other investors [1][3]. Group 2: Financial Misconduct - On June 21, 2023, Yitong Century received an administrative penalty decision from the China Securities Regulatory Commission (CSRC) due to significant financial misconduct [2][3]. - Between May 1 and December 31, 2017, Yitong Century's subsidiary, Beitai Health, engaged in financial fraud, inflating revenue by 97.34 million yuan, costs by 52.61 million yuan, and total profits by 40.84 million yuan, which represented 3.7%, 9.75%, and 15.67% of the company's reported figures, respectively [2][4]. Group 3: Investor Compensation Eligibility - Investors who purchased Yitong Century shares between April 3, 2018, and November 4, 2022, and sold or continued to hold their shares after November 4, 2022, are eligible to file for compensation based on previous favorable judgments [5].